Crown Bioscience is enhancing its existing platform for chimeric antigen receptor (CAR) T-cell agent evaluation with bioluminescent imaging capabilities.   CAR T-cell agents utilize CAR T-cells that recognize tumor-associated antigens and subsequently promote tumor elimination. The efficacy of CAR T-cell compounds has led to hundreds of clinical trials with two notable successes recently approved by the FDA to treat refractory B-cell precursor acute lymphoblastic leukemia (ALL).   ...